Search
Treosulfan
go.drugbank.com/drugs/DB11678ApprovedInvestigational[L52245] It was approved by the EMA in June 2019[L16965] and by the FDA in January 2025 for use in combination with [fludarabine].[L52575] … Treosulfan is a prodrug alternative to [busulfan] for myeloablative conditioning prior to hematopoietic stem cell transplantation.
Categories: Antineoplastic and Immunomodulating AgentsCytohesin-2
go.drugbank.com/bio_entities/BE0002654TargetHumansThe cell membrane form, in association with ARL4 proteins, recruits ARF6 to the plasma membrane (PubMed:17398095). Involved in neurite growth (By similarity) … Promotes guanine-nucleotide exchange on ARF1, ARF3 and ARF6. Activates ARF factors through replacement of GDP with GTP (By similarity).
Synonyms: PH, SEC7 and coiled-coil domain-containing protein 2Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. … [L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant]
Doxercalciferol
go.drugbank.com/drugs/DB06410ApprovedInvestigationalDoxercalciferol is marketed under the brand name Hectoral by Genzyme Corporation, and is manufactured by Catalent Pharma Solutions, Inc. … Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients
Categories: Diet, Food, and Nutrition, Vitamin D and AnaloguesSotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigationalSotrovimab (VIR-7831), also known as GSK4182136, is a monoclonal antibody that can neutralize the SARS-CoV-2 virus. … [L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective.
Categories: Amino Acids, Peptides, and Proteins, Immune Sera and ImmunoglobulinsNerandomilast
go.drugbank.com/drugs/DB18237ApprovedInvestigationalNerandomilast is a phosphodiesterase 4 (PDE4) inhibitor that preferentially inhibits the PDE4B subtype. It has one chiral center and is the R-stereoisomer. … [L54141] Nerandomilast exerts both anti-fibrotic and immunomodulatory effects as PDE4 inhibition elevates intracellular cAMP levels and reduces the expression of pro-fibrotic growth factors and inflammatory
Human papillomavirus type 52 L1 capsid protein antigen
go.drugbank.com/drugs/DB10313ApprovedInvestigationalIt is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) type 52 The vaccine is prepared from the purified virus-like particles … (VLPs) of the major capsid (L1) protein of HPV Type 52 which are produced by separate fermentations in recombinant *Saccharomyces cerevisiae* and self-assembled into VLPs.
Mixtures: GARDASİL 9 IM ENJEKSİYONLUK SÜSPANSİYON, 1 ADET ŞIRINGA+2 ADET İĞNEXimelagatran
go.drugbank.com/drugs/DB04898ApprovedWithdrawnXimelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. … In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries
Categories: Blood and Blood Forming OrgansSynonyms: ethyl 2-[[(1R)-1-cyclohexyl-2- [(2S)-2-[[4-(N'-hydroxycarbamimidoyl) phenyl]methylcarbamoyl]azetidin-1-yl]- 2-oxo-ethyl]amino]acetateElotuzumab
go.drugbank.com/drugs/DB06317ApprovedInvestigationalFood and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. … Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S.
Categories: Amino Acids, Peptides, and Proteins, Antineoplastic and Immunomodulating AgentsBordetella pertussis pertactin antigen
go.drugbank.com/drugs/DB10789ApprovedInvestigationalBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis [A31248].
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Covaxis Injektionssuspension in einer FertigspritzeCategories: Amino Acids, Peptides, and Proteins